Distribution, Metabolism, and Excretion of Gedatolisib in Healthy Male Volunteers After a Single Intravenous Infusion-Reference-Cited by-同舟云学术

Distribution, Metabolism, and Excretion of Gedatolisib in Healthy Male Volunteers After a Single Intravenous Infusion

Published:2018-09-26 Issue:1 Volume:8 Page:22-31
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Houk Brett E.¹,Alvey Christine W.²,Visswanathan Ravi³,Kirkovsky Leonid¹,Matschke Kyle T.⁴,Kimoto Emi²,Ryder Tim²,Obach R. Scott²,Durairaj Chandrasekar¹

Affiliation:

1. Pfizer Oncology; San Diego CA USA

2. Pfizer, Worldwide Research and Development; Groton CT USA

3. Pfizer Worldwide Research and Development; San Diego CA USA

4. Pfizer; Collegeville PA USA

Funder

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpdd.615/fullpdf

Reference17 articles.

1. Targeting PI3K signalling in cancer: opportunities, challenges and limitations;Engelman;Nat Rev Cancer,2009

2. Development of PI3K inhibitors: lessons learned from early clinical trials;Rodon;Nat Rev Clin Oncol,2013

3. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment;Brana;BMC Med,2012

4. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor;Mallon;Clin Cancer Res,2011

5. First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer;Shapiro;Clin Cancer Res,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Method development and validation for the estimation of gedatolisib in mouse plasma by tandem mass spectrometry and its application to pharmacokinetics studies;Biomedical Chromatography;2024-04-10

2. The molecular genetics of PI3K/PTEN/AKT/mTOR pathway in the malformations of cortical development;Genes & Diseases;2023-07

3. Design, conduct, and interpretation of human mass balance studies and strategies for assessing metabolites-in-safety testing (MIST) in drug development;Overcoming Obstacles in Drug Discovery and Development;2023

4. Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors;European Journal of Medicinal Chemistry;2020-10

5. Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists;Clinical Pharmacokinetics;2020-02-13